Promore Pharma: Mixed data (continued)

Research Note

2020-12-02

08:35

Redeye lowers its valuation of Promore Pharma (base case at SEK 6) following mixed study data from its phase IIb trial.

FT

Fredrik Thor

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.